|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?显示文摘Oral mesalazine(also known as mesalamine) is a 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.The therapeutic effect of mesalazine occurs topically at the site of diseased colonic mucosa. A myriad of oral mesalazine preparations have been formulated with various drug delivery methods to minimize systemic absorption and maximise drug availability at the inflamed colonic epithelium. It remains unclear whether different oral mesalazine formulations are bioequivalent. This review aims to evaluate the differences between mesalazine formulations based on the currently available literature and explore factors which may influence the selection of one agent above another. | Bei Ye Daniel R van Langenberg | 2015 | World Journal of Gastrointestinal Pharmacology and Therapeutics2015，6，4： | 14 |
| 2 | Inflammatory bowel disease serology in Asia and the West显示文摘AIM:To study serological antibodies in Caucasians and Asians,in health and inflammatory bowel disease(IBD),in Australia and Hong Kong(HK).METHODS:Anti-glycan antibodies[anti-chitobioside(ACCA),anti-laminaribioside(ALCA)],and anti-mannobioside(AMCA),anti-Saccharomyces cervisiae(gASCA);and atypical perinuclear anti-neutrophil cytoplasmic antibody(pANCA)were tested in IBD patients,their unaffected relatives,and healthy controls in Australia and HK(China).Antibody status(positive or negative)and titre was compared between subjects of different geography,ethnicity and disease state.RESULTS:Ninety subjects were evaluated:21 Crohn’s disease(CD),32 ulcerative colitis(UC),29 healthy controls,and 8 IBD patient relatives.Forty eight subjects were Australian(29 Caucasian and 19 ethnic Han Chinese)and 42 were from HK(all Han Chinese).Caucasian CD patients had a significantly higher antibody prevalence of gASCA(67%vs 3%,P<0.001),ALCA(44%vs 6%,P=0.005),and AMCA(67%vs 15%,P=0.002),whereas HK CD patients had a higher prevalence of only AMCA(58%vs 25%,P=0.035),when compared with UC and healthy subjects in both countries.Caucasian CD had significantly higher gASCA prevalence(67%vs 0%,P<0.001)and titre(median59 vs 9,P=0.002)than HK CD patients.Prevalence and titres of ALCA,ACCA and AMCA did not differ between CD in the two countries.Presence of at least one antibody was higher in Caucasian than HK CD patients(100%vs 58%,P=0.045).pANCA did not differ between countries or ethnicity.CONCLUSION:Serologic CD responses differ between HK Asian and Australian Caucasian patients.Different genetic,environmental or disease pathogenic factors may account for these differences. | Lani Prideaux Michael A Kamm Peter De Cruz Daniel R van Langenberg Siew C Ng Iris Dotan | 2013 | World Journal of Gastroenterology2013，19，37： | 10 |
| 3 | Satisfaction with patient-doctor relationships in inflammatory bowel diseases:Examining patient-initiated change of specialist显示文摘AIM:To assess the reasons for,and factors associated with,patient-initiated changes in treating specialist in inflammatory bowel diseases(IBD).METHODS:Prospectively identified IBD patients(n = 256) with ≥ 1 encounter at a metropolitan hospital were surveyed,including whether they had changed treating specialist and why.Negative reasons included loss of confidence,disagreement,and/or personality clash with the specialist.RESULTS:Of 162 respondents,70(43%) had ever changed specialists;30/70(43%) for negative reasons,52/70(74%) in the preceding year.Patients with negative reasons for changing(n = 30) were younger(median,35.2 years vs 45.3 years),had higher IBD knowledge(median,5.0 years vs 4.0 years),yet had lower medication adherence and satisfaction scores(median,19.0 years vs 22.0 years,14.0 years vs 16.0 years respectively,Mann-Whitney tests,all P < 0.05),compared to all other responders(n = 132).Patients with a recent change(for any reason) were more likely to have Crohn's disease,currently active disease,previous bowel resection and recent hospitalization [OR 2.6,95% CI(1.3-5.4),2.2(1.0-4.7),5.56(1.92-16.67),2.0(1.3-3.0),eachP < 0.05].CONCLUSION:Changing specialist appears associated with patient-related(age,nonadherence) and contemporaneous disease-related factors(recent relapse) which,where modifiable,may enhance patient-doctor relationships and therefore quality of care. | Daniel R van Langenberg Jane M Andrews | 2012 | World Journal of Gastroenterology2012，18，18： | 5 |
| 4 | Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?显示文摘An awareness of the expected time for therapies to induce symptomatic improvement and remission is necessary for determining the timing of follow-up, disease(re)assessment, and the duration to persist with therapies, yet this is seldom reported as an outcome in clinical trials. In this review, we explore the time to clinical response and remission of current therapies for inflammatory bowel disease(IBD) as well as medication, patient and disease related factors that may influence the time to clinical response. It appears that the time to therapeutic response varies depending on the indication for therapy(Crohn's disease or ulcerative colitis). Agents with the most rapid time to clinical response included corticosteroids, calcineurin inhibitors, exclusive enteral nutrition, aminosalicylates and anti-tumor necrosis factor therapy which will work in most patients within the first 2 mo. Vedolizumab,methotrexate and thiopurines had a longer time to clinical response and can take several months to achieve maximal efficacy. Factors affecting the time to clinical response of therapies included use of concomitant therapy, disease duration, smoking status, disease phenotype and advanced age. There appears to be marked variation in time to clinical response for therapies used in IBD which is further influenced by disease and patient related factors. Understanding the expected time to therapeutic response is integral to inform further decision making, maintain a patientcentered approach and ensure treatment is given an appropriate timeframe to achieve maximal benefit prior to cessation. | Abhinav Vasudevan Peter R Gibson Daniel R van Langenberg | 2017 | World Journal of Gastroenterology2017，23，35： | 4 |
| 5 | Isolated subcutaneous implantation of a borderline ovarian tumor:A case report and review of the literature显示文摘Laparoscopy-related tumor implantations of gynecological malignancies into the subcutaneous tissue are rarely diagnosed.We report an interesting case of a 46-year-old female who presented with an abdominal subcutaneous metastasis of a borderline ovarian tumor.The patient received a laparoscopic unilateral adnexectomy for a solid-cystic tumor of the right ovary.Histopathological workup showed a papillary borderline tumor of mucinous type.Nine days later she underwent a hysterectomy,left adnexectomy,appendectomy and omentectomy.Exploration of the peritoneum revealed no intraperitoneal implants.Further exploration showed a non-invasive implant of a borderline tumor in the subcutaneous tissue above the fascia that had no contact to the peritoneum.It is hypothesized that tumor cells may have been implanted during a previous laparoscopy,the most recent of which had been fourteen years prior to her current presentation.Various risk factors for port-site malignancies have been identified.Tumor manipulation and extraction of tumor tissue without a protective bag may contribute to development of trocarsite metastasis. | Malgorzata Banys-Paluchowski Borsu Yeganeh Jutta Luettges Achim Maibach Ruediger Langenberg Natalia Krawczyk Peter Paluchowski Holger Maul Gerhard Gebauer | 2016 | World Journal of Clinical Oncology2016，7，2： | 4 |
| 6 | 厚壁奥氏体焊缝超声波检测之探究(英文)显示文摘由于奥氏体焊缝中材料性能的各向异性和微观组织结构的不同,奥氏体焊缝的超声波检测是非常困难的。超声波在奥氏体焊缝中会沿金属结晶方向发生偏转,并在焊缝边界上发生散射。过去十年来,人们开发了多种模拟各向异性材料中声波传播的仿真工具。本文则以常规超声波检测方法为基础,将声线跟踪法和弹性动力学有限积分技术(EFIT)相结合,应用于含晶间应力腐蚀裂纹的厚壁奥氏体焊缝中,其结果显示声线跟踪法和弹性动力学有限积分技术(EFIT)结合应用,有助于超声波检测参数的选取。 | Han T Y Khler B Schmitz V Zimmer A Langenberg K J | 2009 | 无损检测2009，31，11： | 3 |
| 7 | Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study显示文摘BACKGROUND Traditional methods of developing predictive models in inflammatory bowel diseases(IBD)rely on using statistical regression approaches to deriving clinical scores such as the Crohn's disease(CD)activity index.However,traditional approaches are unable to take advantage of more complex data structures such as repeated measurements.Deep learning methods have the potential ability to automatically find and learn complex,hidden relationships between predictive markers and outcomes,but their application to clinical prediction in CD and IBD has not been explored previously.AIM To determine and compare the utility of deep learning with conventional algorithms in predicting response to anti-tumor necrosis factor(anti-TNF)therapy in CD.METHODS This was a retrospective single-center cohort study of all CD patients who commenced anti-TNF therapy(either adalimumab or infliximab)from January 1,2010 to December 31,2015.Remission was defined as a C-reactive protein(CRP)<5 mg/L at 12 mo after anti-TNF commencement.Three supervised learning algorithms were compared:(1)A conventional statistical learning algorithm using multivariable logistic regression on baseline data only;(2)A deep learning algorithm using a feed-forward artificial neural network on baseline data only;and(3)A deep learning algorithm using a recurrent neural network on repeated data.Predictive performance was assessed using area under the receiver operator characteristic curve(AUC)after 10×repeated 5-fold cross-validation.RESULTS A total of 146 patients were included(median age 36 years,48%male).Concomitant therapy at anti-TNF commencement included thiopurines(68%),methotrexate(18%),corticosteroids(44%)and aminosalicylates(33%).After 12 mo,64%had CRP<5 mg/L.The conventional learning algorithm selected the following baseline variables for the predictive model:Complex disease behavior,albumin,monocytes,lymphocytes,mean corpuscular hemoglobin concentration and gamma-glutamyl transferase,and had a cross-validated AUC of 0.659,95%confidence interval(CI):0.562-0.756.A feed-forward artificial neural network using only baseline data demonstrated an AUC of 0.710(95%CI:0.622-0.799;P=0.25 vs conventional).A recurrent neural network using repeated biomarker measurements demonstrated significantly higher AUC compared to the conventional algorithm(0.754,95%CI:0.674-0.834;P=0.036).CONCLUSION Deep learning methods are feasible and have the potential for stronger predictive performance compared to conventional model building methods when applied to predicting remission after anti-TNF therapy in CD. | Danny Con Daniel R van Langenberg Abhinav Vasudevan | 2021 | World Journal of Gastroenterology2021，27，38： | 2 |
| 8 | Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford显示文摘BACKGROUND Vedolizumab(VDZ),a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis(UC)patients.AIM To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission.METHODS A retrospective review of Australian and Oxford,United Kingdom data for UC patients.Clinical response at 3 mo,endoscopic remission at 6 mo and clinical remission at 3,6 and 12 mo were assessed.Cox regression models and Kaplan Meier curves were performed to assess the time to remission,time to failure and the covariates influencing them.Safety outcomes were recorded.RESULTS Three hundred and three UC patients from 14 centres in Australia and United Kingdom,[60%n=182,anti-TNF naïve]were included.The clinical response was 79%at 3 mo with more Australian patients achieving clinical response compared to Oxford(83%vs 70%P=0.01).Clinical remission for all patients was 56%,62%and 60%at 3,6 and 12 mo respectively.Anti-TNF naive patients were more likely to achieve remission than exposed patients at all the time points(3 mo 66%vs 40%P<0.001,6 mo 73%vs 46%P<0.001,12 mo 66%vs 51%P=0.03).More Australian patients achieved endoscopic remission at 6 mo compared to Oxford(69%vs 43%P=0.01).On multi-variate analysis,anti-TNF naïve patients were 1.8(95%CI:1.3-2.3)times more likely to achieve remission than anti-TNF exposed(P<0.001).32 patients(11%)had colectomy by 12 mo.CONCLUSION VDZ was safe and effective with 60%of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome. | Samba Siva Reddy Pulusu Ashish Srinivasan Krupa Krishnaprasad Daniel Cheng Jakob Begun CharlotteKeung Daniel Van Langenberg Lena Thin Tamara Mogilevski Peter De Cruz Graham Radford-Smith Emma Flanagan Sally Bell Soleiman Kashkooli Miles Sparrow Simon Ghaly Peter Bampton Elise Sawyer Susan Connor Quart-ul-ain Rizvi Jane M Andrews Gillian Mahy Paola Chivers Simon Travis Ian Craig Lawrance | 2020 | World Journal of Gastroenterology2020，26，30： | 2 |
| 9 | Ni2 revisited: Reassignment of the ground electronic state显示文摘 | Pinegar J C Langenberg J D Arrington C A | 1994 | J Chem Phys1994，102，： | 1 |
| 10 | New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk显示文摘 | Dupuis J Langenberg C Prokopenko I | 2010 | Nat Genet2010，42，2： | 1 |
| 11 | mi Ranalyzer:a micro RNA detection and analysis tool for next-generation sequencing experiments显示文摘 | Hackenberg M Sturm M Langenberger D | 2009 | Nucleic Acids Research2009，37，： | 1 |
| 12 | Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study显示文摘 | Zheng Ye Stephen J Sharp Stephen Burgess Robert A Scott Fumiaki Imamura Claudia Langenberg Nicholas J Wareham Nita G Forouhi | 2015 | The Lancet Diabetes & Endocrinology2015，，1： | 1 |
| 13 | New method for retrospective detection of exposure to organophsphorus anticholinesterase: application to alleged sarin victims of Japanese terrorists显示文摘 | Langenberg JP Benschop H | 1997 | Toxicol Appl Pharmacol1997，146，1： | 1 |
| 14 | Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-γ-dependent mechanism显示文摘 | Netea M G Azam T Lewis E C Joosten L A Wang M Langenberg D Meng X Chan E D Yoon D Y Ottenhoff T Kim S H and Dinarello C A | | 0，，08： | 1 |
| 15 | The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study显示文摘 | Newman NJ Scherer R Langenberg P | 2002 | Am J Ophthalmol2002，134，3： | 1 |
| 16 | Human 11,-23- producing type 1 macrophages promote but IL-10-produciug type 2 macrophages subvert immunity to (myco) bacteria 显示文摘 | Verreek FA de Boer T Langenberg DM | 2004 | Pmc Natl Acad Sci USA2004，101，13： | 1 |
| 17 | Effective-ness of acupuncture as adjunctive therapy in osteoar-thritis of the knee:a randomized,controlled trial显示文摘 | Berman B M Lao L Langenberg P | 2004 | Ann Intern Med2004，141，12： | 1 |
| 18 | An efficient wheat transformation procedure: transformed calli with long-term morphogenic potential for plant regeneration 显示文摘 | Zhang L Rybczynski J J Langenberg W G | 2000 | Plant Cell Reports2000，19，： | 1 |
| 19 | Genetic evidence that raised sex hormone binding globulin (SHBG)levels reduce the risk of type 2 diabetes 显示文摘 | Perry JR Weedon MN Langenberg C | 2010 | Hum Mol Genet2010，19，3： | 1 |
| 20 | Seropositivityand Higher Immunoglobulin G Antibody Levels Against Cytomega-lovirus Are Associated With Mortality in the Population-Based Eu-ropean Prospective Investigation of Cancer-Norfolk Cohort 显示文摘 | Gkrania-Klotsas E Langenberg C Sharp SJ | 2013 | Clin Infect Dis2013，56，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员